Survey ranking reinforces Company’s industry-leading position as CRO of Choice for sites Only company to rank consistently among top three CROs in every survey over the last decade Company rated a top three CRO on all 37 individual relationship attributes noted as important to sites
RALEIGH, N.C., April 03, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq: INCR ), a leading, global Phase I to IV contract research organization, is ranked “Top CRO to Work With” among the top 10 global CROs in the biannual CenterWatch Global Investigative Site Relationship Survey, building on the Company’s previous strong performance on this survey. Results of the 2017 survey were published earlier today by CenterWatch, the leading provider of global clinical trials information. INC Research previously ranked “Top CRO to Work With” among large global CROs in 2015 and also received the top ranking in CenterWatch’s global investigative site relationship survey completed in 2013. INC is the only CRO to rank consistently among the top three CROs in all eight CenterWatch site relationship surveys conducted over the past decade.
“INC Research is pleased to once again be ranked by clinical research sites globally as their CRO of Choice,” says Alistair Macdonald, Chief Executive Officer at INC Research. “From our perspective, the survey results reaffirm that INC’s approach to working with sites has become the industry benchmark. We have consistently used our relationships, as well as the data we have acquired from multiple sources, to pick the right sites, to run the right protocol, and to help our customers find the right patients. This winning combination manifests itself in our superior operational delivery. We believe our continued strong ranking is a direct reflection of our ongoing focus on sites as partners in the clinical development process and our commitment to building long-term collaborative relationships that are mutually beneficial. It is one way INC is able to demonstrate its proven track record in investigator relations over the past decade.”
“The feedback we’ve received from clinical research sites through the 2017 CenterWatch survey is extremely important to us,” notes Clare Grace, PhD, Vice President, Site and Patient Access. “Participants’ opinions about their professional experiences and working relationship with INC Research help us continually improve the way we work with them, as our scores show. Sites have said they want to work with professional CRAs and CMAs who are well-trained and knowledgeable. They value open communication and the effective use of communication technology, and they want staff that are accessible and able to escalate and resolve issues. Additionally, sites have been very clear about their desire to work with a CRO who provides prompt investigator payments. We’ve invested a great deal of time, energy and resources into these areas that are most important to sites, and we’re very pleased our efforts have been recognized as evidenced by our CenterWatch ranking.”
CenterWatch’s 2017 Global Investigative Site Relationship Survey was conducted online between November 2016 and January 2017 and included participation from principal investigators, sub-investigators and study coordinators at more than 1,300 global investigative sites across 15 countries. INC Research’s combined excellent ratings in the 2017 CenterWatch survey were higher compared to 2015 survey results, a testament to the Company’s ongoing and proactive collaboration and support of sites in the areas that matter most to them. Rankings in the CenterWatch survey are based on a combination of two measures: an overall relationship quality rating based on “excellent” scores from sites, and the frequency with which companies placed among the top-three rated CROs across all relationship attributes measured. INC Research ranked among the top-three CROs in all the 37 attributes measured. Overall, the average CRO “excellent” rating on individual attributes has steadily improved since 2013.
INC Research’s top ranking in the CenterWatch survey reflects the Company’s continued and significant focus on site relationships to enhance its delivery of global clinical development programs for biopharmaceutical customers worldwide. INC Research has served as a Global Impact Partner since 2014 and is the only Circle of Innovation Sponsor (the highest level of partnership) for the Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites. As a Circle of Innovation Sponsor, INC Research has funded more than 500 Site Scholarships for SCRS membership that provide the training, mentorship and advocacy that sites need to become members of a world-class clinical research community. INC Research is also actively working with SCRS to strengthen and grow its global membership through the SCRS Ambassador Program, which aims to extend SCRS membership and support to sites globally through regional activity around the world. INC is committed to recognizing the contributions of its site partners globally through programs such as the INC Research Clinical Research Site Award, through which more than 300 awards have been given to date.
In 2016 INC launched the Catalyst program to strengthen collaborations with clinical research sites worldwide, in turn enhancing patient focus and optimizing study delivery to drive improved predictability of clinical trials and reduce development timelines for biopharmaceutical customers worldwide. The program includes two components — the Catalyst Site Network and the Catalyst Community — which focus on developing stronger collaborations with clinical research sites across the globe to drive continuous improvement and development of best practice in the delivery of clinical research. The program incorporates INC’s Trusted Process™ clinical development methodology, which focuses on reducing variability and increasing predictability to improve the conduct of clinical trials.
About INC Research INC Research (Nasdaq: INCR ) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked “Top CRO to Work With” among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research .
CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: Investor.Relations@incresearch.com Press/Media Contacts: Lori Dorer Senior Director, Corporate Communications Phone: +1 (919) 745-2890 Email: Corporate.Communications@incresearch.com
